Immunomodulatory effects of interferon-β-1b in patients with multiple sclerosis

International Immunopharmacology

Volumn 1, Issue 6, 2001, Pages 1085-1100

  Ossege, L M ^a   Sindern, E ^a   Patzold, T ^a   Malin, J P ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Immunomodulatory therapy; Interferon beta 1b; Lymphocyte subsets; Multiple sclerosis; Soluble vascular adhesion molecule 1; TGF beta receptor type II; TGF 1; TNF ; TNF receptor type I

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; INTERFERON BETA SERINE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ADULT; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION; INTERFERON-BETA; LYMPHOCYTE SUBSETS; MALE; MULTIPLE SCLEROSIS; RNA, MESSENGER; TISSUE FIXATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035038929     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00039-X     Document Type: Review

References (84)

1. McFarlin D.E., McFarland H.F. Multiple sclerosis. N. Engl. J. Med. 307:1982;1183-1188.
2. Raine C.S. The Dale E. McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann. Neurol. 36:1994;S61-S72.
3. Clinical results of a multicenter, randomized, double-blind placebo controlled trail. Neurology. 43:1993;655-661.
4. Paty D.W., Li D.K.B. Interferon β 1b is effective in relapsing and remitting multiple sclerosis: II. MRI analysis results of amulticenter, randomized, double-blind placebo controlled trail. Neurology. 43:1993;662-667.
5. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A.et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
6. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
7. Ossege L.M., Sindern E., Voss B., Malin J.P. Corticosteroids induce expression of transforming-growth-factor-beta1 mRNA in peripheral blood mononuclear cells of patients with multiple sclerosis. J. Neuroimmunol. 84:1998;1-6.
8. Pitzalis C., Sharrack B., Gray I.A., Lee A., Hughes R.A.C. Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression, T cell subsets distribution and TNF alpha concentrations in multiple sclerosis. J. Neuroimmunol. 74:1997;62-68.
9. Drissen C., Hirv K., Wellinghausen N., Kirchner H., Rink L. Influence of serum on zinc, toxic shock syndrome toxin-1, and lipopolysaccharide-induced production of IFN-γ and IL-1β by human mononuclear cells. J. Leukocyte Biol. 57:1995;904-908.
10. Denhardt D.T. A membrane filter technique for detection of complementary DNA. Biochem. Biophys. Res. Commun. 23:1966;641-646.
11. Lin H.Y., Wang X.F., Ng-Eaton E., Weinberg R.A., Lodish H.F. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell. 68:1992;775-785.
12. Himmler A., Maurer-Fogy I., Scheurich P., Pfizenmaier K., Lantz M.et al. Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein. DNA Cell Biol. 9:1990;705-715.
13. Ogden R.C., Adams D. Electrophoresis in agarose und acrylamide gels. Berger S.L., Kimmel A.R. Guide to Molecular Cloning Technique. Methods in Enzymology. vol. 152:1987;61-87 Academic Press, Orlando.
14. Feinberg A.P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:1983;6-13.
15. Ossege L.M., Voss B., Wiethege T., Sindern E., Malin J.P. Detection of transforming growth factor beta1 mRNA in cerebrospinal fluid cells in patients with meningitis by non-radioactive in situ hybridization. J. Neurol. 242:1994;14-19.
16. Balkwill F.R. Interferons. Lancet. 1:1989;1060-1063.
17. Satoh J.I., Paty D.W., Kim S.U. Differential effects of beta and gamma interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes. Neurology. 45:1995;367-373.
18. Ling P.D., Warren M.K., Vogel S.N. Antagonistic effect of interferon beta on the interferon gamma induced expression of Ia antigen in murine macrophages. J. Immunol. 135:1985;1857-1863.
19. Huynh H.K., Oger J., Dorovini-Zis K. Interferon-β downregulated interferon-γ-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J. Neuroimmunol. 60:1995;63-73.
20. Miller A., Lanir N., Shapiro S., Revel M., Honigman S., Kinarty A.et al. Immunoregulatory effects of interferon-β and interacting cytokines on human vascular endothelial cells: implications for multiple sclerosis and other autoimmune diseases. J. Neuroimmunol. 64:1996;151-161.
21. Arnason B.G.W. Short analytical review: interferon beta in multiple sclerosis. Clin. Immunol. Immunopathol. 81:1996;1-11.
22. Genc K., Reder A.T. IFNβ-1b reverses elevated lymphocyte B7-1 in MS. J. Neuroimmunol. 52 (Suppl):1995;20. (Abstract).
23. Leppert D., Waubant E., Bürk M.R., Oksenberg J.R., Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1996;846-852.
24. Rep M.H.G., Hintzen R.Q., Polman C.H., van Lier R.A.W. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 67:1996;11-118.
25. Stüve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S.et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects in matrix metalloproteinase-9. Ann. Neurol. 40:1996;853-863.
26. Noronha A., Toscas A., Jense M.A. Interferon beta augments suppressor cell function in multiple sclerosis. Ann. Neurol. 27:1990;207-210.
27. Noronha A., Toscas A., Jensen M.A. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J. Neuroimmunol. 46:1993;1605-1621.
28. Porrini A.M., Gambi D., Reder A.T. Interferon effects on interleukin-10 secretion; mononuclear cell response to interleukin-10 is normal in multiple sclerosis. J. Neuroimmunol. 61:1995;27-34.
29. Rep M.H.G., Hintzen R.Q., Polman C.H., van Lier R.A.W. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 67:1996;11-118.
30. Rep M.H.G., Schrijver H.M., van Lopik T., Hintzen R.Q., Roos M.T.L., Adèr H.J.et al. Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patients. J. Neuroimmunol. 96:1999;92-100.
31. Kekow J., Gross W.L. Transforming growth factor beta: Wirkungsweise und klinische Bedeutung. Dtsch. Med. Wochenschr. 117:1992;228-235.
32. Rook A.H., Kehrl J.H., Wakefield L.M., Roberts A., Sporn M.B., Burlington D.B. Effects of transforming growth factor beta on the functions of ,natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136:1986;3916-3920.
33. Shalaby M.R., Ammann A.J. Suppression of immune cell function in vitro by recombinant human transforming-growth-factor-beta. Cell Immunol. 112:1988;343-350.
34. Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature. 334:1988;260-262.
35. Sugarman B.J., Lewis G.D., Essalu T.E., Aggarwal B.B., Shepard H.M. Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res. 37:1987;780-786.
36. Robert A.B., Sporn M.B. Transforming growth factor beta. Adv. Cancer Res. 51:1988;107-145.
37. Chen R.H., Moses H.L., Maruoka E., Derynck R., Kawabata M. Phosphorylation-dependent interaction of the cytoplasmic domain of the type I and type II transforming growth factor-β receptors. J. Biol. Chem. 270:1995;12235-12241.
38. Link J., Fredrikson S., Söderström M., Olsson T., Höjeberg B.et al. Organ-specific autoantigens induce transforming growth factor-β mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Ann. Neurol. 35:1994;197-203.
39. Sindern E., Schweppe K., Ossege L.M., Malin J.P. Potential role of transforming growth factor-β1 in terminating the immune response in patients with Guillain-Barré syndrome. J. Neurol. 243:1996;264-268.
40. Jung S., Schluesener H.J., Schmidt B., Fontana A., Toyka K.V. Therapeutic effect of transforming growth factor-β2 on actively induced EAN but not adoptive transfer EAN. Neurology. 83:1994;545-551.
41. Olsson T. Role of cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis. Eur. J. Neurol. 1:1994;7-19.
42. Link J., Söderström M., Olsson T., Höjeberg B., Ljingdahl A., Link H. Increased transforming growth factor-β, interleukin-4, and interferon-γ in multiple sclerosis. Ann. Neurol. 36:1994;379-386.
43. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H.et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 44:1994;1523-1526.
44. Noronha A., Jensen M., Toscas A. TGF-β activity in MS: effect of IFN-β Neurology. 43(Suppl.):1993;355.
45. Yasuda C.L., Al-Sabbagh A., Oliveira E.C., Diaz-Bardales B.M., Garcia A.A., Santos L.M. Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion. Immunol. Invest. 28:1999;115-126.
46. Nicoletti F., Di Marco R., Patti F., Reggio E., Nicoletti A., Zaccone P.et al. Blood levels of transforming-growth-factor-beta 1 (TGF-β1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-β1b). Clin. Exp. Immunol. 113:1998;96-99.
47. Matusevicius D., Kivisakk P., Navikas V., Tian W., Soderstrom M., Fredrikson S.et al. Influences of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. Eur. J. Neurol. 5:1998;265-275.
48. Massague J. Subuntit structure of a high-affinity receptor for type beta-transforming growth factor. Evidence for a disulfide-linked glycosylated receptor complex. J. Biol. Chem. 260:1985;7059-7066.
49. Wakefield L.M., Smith D. Distribution and modulation of the cellular receptor for transforming growth factor-beta. J. Cell Biol. 105:1987;965-975.
50. Old L.J. Tumor necrosis factor. Science. 230:1985;630-632.
51. Dustin M.L., Springer T.A. Lymphocyte-function-associated antigen-1. Interaction with cellular adhesion molecule-1 (ICAM-1) is one of the least three mechanisms for lymphocyte adhesion to culture endothelial cells. J. Cell Biol. 321:1988;321-331.
52. Osborne L., Hession C., Tizard R., Vassalo C., Luhowskyi S.et al. Direct expression cloning of vascular cell adhesion molecule-1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell. 59:1989;1203-1211.
53. Dixit V.M., Green S., Sarma V., Holzmann L.B., Wolf F.W.et al. Tumor necrosis factor-α induction of novel gene products in human endothelial cells including a macrophage-specific chemotoxin. J. Biol. Chem. 165:1990;2973-2978.
54. Streiter R.M., Kunkel S., Showell H.J., Remick D.G., Phan S.H.et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-α, LPS, and IL-1β Science. 241:1989;1467-1469.
55. Kaushansky K., Broudy V.C., Harlan J.M., Adamson J.W. Tumor-necrosis-factor-α and tumor-necrosis-factor-β (lymphotoxin) stimulate the production of granulocyte macrophage colony-stimulating factor, macrophage-stimulating factor and IL-1 in vivo. J. Immunol. 141:1988;3410-3415.
56. Kohase M., Hendrikson-DeStefano D., May L.T., Vilcek J., Sehgal P.B. Introduction of β2-interferon by tumor necrosis factor: a hemostatic mechanism in the control of cell proliferation. Cell. 45:1986;659-666.
57. Hughes C.C.W., Male D.K., Lantos P.L. Adhesion of lymphocytes to cerebral microvascular cells: effects of interferon-γ, tumor necrosis factor and interleukin 1. Immunology. 64:1988;677-681.
58. Exley A.R., Smith N., Winer J.B. Tumor nerosis factor-A and other cytokines in Guillain-Barré syndrome. J. Neurol., Neurosurg., Psychiatry. 57:1994;118-1120.
59. Rieckmann P., Albrecht B.A., Kitze B., Weber T., Tumani H.et al. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 37:1995;82-88.
60. Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J. Exp. Med. 172:1990;599-607.
61. Mohler K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E.et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1993;1548-1561.
62. Van Zee K., Kohno T., Fischer E., Rock C.S., Moldawer L., Lowry S.F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 89:1992;4845-4849.
63. Selmaj K.W., Papierz W., Glabinski A., Kohono T. Prevention of chronic relapsing experimental autoimmune encephalitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol. 56:1995;135-141.
64. Gayo A., Mozo L., Suarez A., Tunon A., Lahoz C., Gutierrez C. Interferon beta-1b treatment modulates TNF-alpha and IFN-gamma spontaneous gene expression in MS. Neurology. 52:1999;1764-1770.
65. Khademi M., Wallstrom E., Andersson M., Piehl F., Di Marco R., Olsson T. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis. J. Neuroimmunol. 103:2000;202-210.
66. Byskosh P.V., Reder T. Interferon β-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult. Scler. 1:1996;262-269.
67. Abu Kahbar K.S., Armstrong J.A., Ho M. Type I interferons (IFN-alpha and-beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells. J. Leukocyte Biol. 52:1992;165-172.
68. Troiano M., Avolio C., Ruggierei M., Defazio G., Guiliani F., Paolicelli D.et al. Antiinflammatory effects of rIFNβ-1b in multiple sclerosis (MS): longitudinal changes of the serum soluble intercellular adhesion molecule-1 (sICAM-1), TNFα and T cell subsets. Neurology. 48:1997;244. (Abstract).
69. Rothuizen L.E., Buclin T., Spertini F., Trinchard I., Munafo A., Buchwalder P.A.et al. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J. Neuroimmunol. 99:1999;131-141.
70. Brod S.A., Marshall G.D. Jr., Henninger E.M., Sriram S., Khan M., Wolinsky J.S. Interferon-β-1b treatment decreases tumor necrosis factor-α and increases interleukin-6 production. Neurology. 46:1996;1633-1638.
71. Hartung H.P. Pathogenesis of inflammatory demyelination: implications for therapy. Current Opinion in Neurology. 8:1995;191-199.
72. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1994;301-314.
73. Pigott R., Dillon L.P., Hemingway I.H., Gearing A.J.H. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatant of cytokine-activated cultured endothelial cells. Biochem. Biophys. Res. Commun. 187:1992;584-589.
74. Dore-Duffy P., Newman W., Balabanov R., Lisak R.P., Mainolfi E.et al. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with disease activity. Ann. Neurol. 37:1995;55-62.
75. Matsuda M., Tsukada N., Koich M., Yanagisawa N. Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus Type-1-associated myelopathy. J. Neuroimmunol. 59:1995;35-40.
76. Hartung H.P., Reiners K., Archelos J.J., Michels M., Seeldrayers P.J.et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann. Neurol. 38:1995;186-193.
77. Gelati M., Corsini E., Dufour A., Massa G., La Mantia L., Milanses C.J.et al. Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up. J. Neurol. 246:1999;569-573.
78. Calabresi P.A., Tranquill L.R., Dambrosi J.M., Stone L.A., Maloni H.et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated in interferon β-1b. Ann. Neurol. 41:1997;669-674.
79. Calabresi P.A., Peltey C.M., Tranquill L.R., Matoni H., McFarland H.F. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology. 49:1997;1111-1116.
80. Arnason B.G.W., Antel J.P. Suppressor cell function in multiple sclerosis. Ann. Immunol. (Paris). 129C:1985;159-170.
81. Antel J.P., Arnason B.G.W., Medorf M.E. Suppressor cell function in multiple sclerosis:correlation with clinical disease activity. Ann. Neurol. 5:1979;338-342.
82. Antel J., Bania M.B., Reder A., Cashman N. Activated suppressor cell dysfunction in progressive multiple sclerosis. J. Immunol. 137:1985;137-141.
83. Miller A., Lide O., Roberts A.B., Sporn M., Weiner H.L. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc. Natl. Acad. Sci. U. S. A. 89:1992;421-425.
84. De Luca G., Lugaresi A., Iarlori C., Marzoli F., Uncini A., Gambi D. Interferon beta normalizes suppressor cell function in dysimmune neuropathies. J. Neuroimmunol. 82:1998;1-4.